Inosine is an oral purine nucleoside being developed as a disease-modifying treatment for Parkinson's disease (PD). The therapeutic approach aims to raise systemic urate levels, leveraging urate's potent antioxidant properties to protect dopaminergic neurons from oxidative stress—key driver of PD pathophysiology [1]. Inosine supplementation has completed Phase 2/3 clinical testing (SURE-PD3 trial), making it one of the most advanced disease-modifying candidates targeting oxidative stress in PD.
Urate (uric acid) is the final product of purine metabolism in humans:
| Property | Relevance to PD |
|---|---|
| Potent antioxidant | Scavenges free radicals |
| Metal chelation | Binds iron, prevents Fenton reaction |
| Nitric oxide modulation | Reduces nitrosative stress |
| Parkinson's epidemiology | Higher urate = slower progression |
Inosine raises urate through the purine degradation pathway [2]:
The connection between urate and PD is supported by:
The pivotal Phase 2/3 trial evaluated inosine in early Parkinson's disease [4]:
| Parameter | Details |
|---|---|
| Phase | Phase 2/3 |
| Enrollment | 298 patients |
| Duration | 24 months |
| Design | Randomized, double-blind, placebo-controlled |
| Dose titration | To achieve target serum urate |
| Finding | Significance |
|---|---|
| Slower progression in males | Suggested benefit in men |
| Trend in motor scores | Encouraging signal |
| Dose-response relationship | Higher urate = better outcomes |
| Marker | Change | Interpretation |
|---|---|---|
| Serum urate | Increased | Target engagement achieved |
| CSF urate | Increased | CNS penetration confirmed |
| Oxidative stress markers | Reduced | Pharmacodynamic effect |
Inosine was generally well-tolerated:
| Adverse Event | Frequency | Notes |
|---|---|---|
| Gout/flare | 5-10% | Manageable with colchicine |
| Kidney stones | Rare | Increased hydration recommended |
| GI symptoms | Mild | Usually transient |
| Candidate | Target | Stage | Mechanism |
|---|---|---|---|
| Inosine | Urate | Phase 2/3 | Antioxidant |
| GDNF | Dopamine neurons | Phase 2 | Growth factor |
| Amodiaquine | Neuroinflammation | Phase 3 | Anti-inflammatory |
| Inosine | Alpha-synuclein | Research | Aggregation inhibition |
As of the latest data: